Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
1. Vigil's VG-3927 shows safety and tolerability in Alzheimer's Phase 1 trial. 2. 50% reduction of sTREM2 in CSF indicates strong drug efficacy. 3. The company plans to start Phase 2 trials in Q3 2025. 4. Analyst calls results encouraging, highlighting consistent target engagement. 5. Vigil is undervalued relative to cash and growth prospects.